Apply to trial NCT06397313

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening